Pinsent Masons advises Bryan, Garnier & Co on Heidelberg Pharma AG’s capital increase

28 Jun 2021 | 02:23 pm |

Multinational law firm Pinsent Masons has advised Bryan, Garnier & Co on the successful EUR 20m capital increase of Heidelberg Pharma AG.

The transaction increased German based biopharmaceutical company Heidelberg Pharma AG’s share capital by approximately 10%, with the 3,106,637 newly issued shares offered to qualified institutional investors in Europe and the United States in an accelerated book-building process. At a subscription price of EUR 6.44 per share, the company raised gross proceeds of EUR 20 million.

The new shares were admitted to trading on the Frankfurt Stock Exchange on June 21, 2021.

Pinsent Masons advised Bryan, Garnier & Co, the sole global coordinator and sole bookrunner for the transaction. Bryan, Garnier & Co is one of the most active investment banks in the European growth sector, with a particular focus on healthcare, technology, consumer goods and business services. They are a fully registered broker-dealer, licensed and supervised by the FCA in Europe and FINRA in the US.

The Pinsent Masons team was led by Dr Susanne Lenz, LL.M. and included Roberta Markovina (Partner, London), Dušan Stojković (Senior Associate, Frankfurt) and Sara Šepac (Associate, Frankfurt).

Commenting on the transaction, Dr Susanne Lenz said:

"We are pleased to have worked with Bryan Garnier on this exciting and important transaction. With Heidelberg Pharma AG’s expertise in oncology, we are proud to have been part of the successful financing of a company on the cutting edge of biopharmaceutical research and development in Germany."

Latest press releases

Show me all press releases

Pinsent Masons advises PIC on £132m buy-in of Tomkins 2008 pension scheme retirement benefits plan

Pinsent Masons advises PIC on £132m buy-in of Tomkins 2008 pension scheme retirement benefits plan.

Pinsent Masons advises on Umicore’s € 591 million sustainability linked note fundraising

Multinational law firm Pinsent Masons has advised various institutional investors in relation to Umicore’s € 591 million sustainability linked note fundraising.

Pinsent Masons advises Alveo on its sale to Symphony Technology Group

Pinsent Masons has advised the shareholders of Alveo, including funds managed by Sovereign Capital Partners (SCP), on its sale to Symphony Technology Group (STG).

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons advises cyber security company StarLink on its merger with Infinigate GmbH

Multinational law firm Pinsent Masons advised the shareholders of a GCC-based cyber and cloud security company StarLink DMCC on its strategic merger with Infinigate GmbH a leading distributor of cyber security in Europe and portfolio company of private equity firm Bridgepoint.

Pinsent Masons appoints Martin Hayward as new technology partner in Dubai

Multinational law firm Pinsent Masons has launched its Middle Eastern Technology, Media Telecoms (TMT) offering with the hire of TMT partner Martin Hayward in the wake of significant developments for digitalisation in the region.

Pinsent Masons advises climate-tech venture capital fund, Systemiq Capital, on the $70m closing of its second fund

Multinational law firm Pinsent Masons has advised climate-tech VC fund Systemiq Capital on the $70 million first close of its second fund, targeting $200 million to continue backing the best early-stage climate tech entrepreneurs.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts

We are processing your request. \n Thank you for your patience. An error occurred. This could be due to inactivity on the page - please try again.